Jb Chemicals & Pharmaceuticals Ltd. · NSE:JBCHEPHARM
Jb Chemicals & Pharmaceuticals — Q2 FY24 Earnings Presentation
26 slides from Jb Chemicals & Pharmaceuticals's earnings presentation, Nov 7, 2023
Slide 1: Company Presentation filing letter to NSE
November 7, 2023 National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G-Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400051. Stock Symbol: JBCHEPHARM Dear Sir, Sub: Company Presentation Enclosed is Company’s presentation on financial results for the quarter and half
Slide 2: JB Pharma – Q2 and H1 FY24 Investor Presentation
JB Pharma – Q2 and H1 FY24 Investor Presentation November 7, 2023 www.jbpharma.com jbpharma/
Slide 3: Disclaimer
Disclaimer No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the d
Slide 4: Synergistic acquisitions, domestic outperformer, consistency of delivery
>. Synergistic acquisitions productivity Domestic outperformer Jp) “ E Gl leader Consistency of delivery _ Strong FCF forG000 HEALTH o — Dosage i i op Global regulatory approvals Medicated/Herbal lozenges a . 3 Leadership Key therapies Pillar Brands e she B PHARMA °s Dosage forms State of the art fa
Slide 5: Company key facts and strengths
46 6 40+ Top 5 Brands among top 300 brands Regulated/semi-regulated Global manufacturer of Years of operations with (IQVIA MAT Sep’23 data), markets of presence through medicated/herbal lozenges consistent track record across contributing over 60% of direct operations and representing a substantial
Slide 6: Corporate Snapshot – Financial Overview
Corporate Snapshot – Financial Overview Revenue (INR cr) PAT (INR cr) ^Op EBITDA Margin (%) ROE (%) ROCE (%) 27.4% 42% 25.0% 24.3% 21.3% 18.6% 3,149 29% 15.4% 24% # 2,424 22% 21% 2,043 25% 1,643 1,775 15% 1,413 19% 18% 17% 449 410 13% 272 386 139 194 10% FY18 FY19 FY20 FY21 FY22 FY23 FY18 FY19 FY20
Slide 7: World Class Manufacturing Facilities
World Class Manufacturing Facilities 8 40+ 10 State of the Art Global Dosage forms manufacturing Regulatory produced facilities Accreditations Tablets Capsules Liquids IV Infusions Ampules Vials Ointments Cold Rubs Lozenges Sips 6
Slide 8: Q2 and H1 FY24 Business Performance
Q2 and H1 FY24 Business Performance
Slide 9: CEO's Message
CEO’s Message “During Q2, the business delivered a healthy blend of domestic and international business growth, with expansion in domestic business led by our chronic segment and acquired portfolio. Our transformed go-to-market framework is driving gains in market share and improvement in our rankin
Slide 10: Results Overview: Q2 and H1 FY24
Results Overview: Q2 and H1 FY24 Revenues (INR crores) 12% 9% o JB Pharma recorded YoY revenue growth of 9% to INR 1,594 1,778 882 crores in Q2 FY24 and 12% to INR 1778 crores in H1 FY24 809 882 • Overall revenue growth impacted by the strategic choices made in international business Q2 FY23 Q2 FY24
Slide 11: EBITDA Analysis
EBITDA Analysis INR crore Q2 FY24 Q2 FY23 H1 FY24 H1 FY23 Revenue 882 809 1778 1594 Reported EBITDA 244 185 476 357 Non Cash ESOP Charge 7 17 18 35 Included in Employee Benefits expense Operating EBITDA (excluding ESOP charge) 251 202 494 392 Operating EBITDA margins 28.5% 25.0% 27.8% 24.6% 10
Slide 12: Financial Overview Q2 and H1 FY24
Financial Overview Q2 and H1 FY24 Op. EBITDA (INR crores) o Operating EBITDA witnessed YoY improvement of 24% in Q2 27.8% FY24 and 26% in H1 FY24 28.5% 24.6% • Operating EBITDA margin stood at 28.5% in Q2 FY24 494 and at 27.8% in H1 FY24 25.0% 392 26% 251 202 o Gross Margin was 66.2% for the quarter
Slide 13: Domestic Business Q2 and H1 FY24
Domestic Business Q2 and H1 FY24 Domestic Formulations (INR crores) o Domestic business grew 11% to INR 481 crores in Q2 14% FY24 vs INR 434 crores in Q2 FY23 • Business grew 14% to INR 970 crores in H1 FY24 vs INR 853 crores in H1 FY23 970 11% o Chronic segment performed well in Q2 FY24 and H1 FY24
Slide 14: JB continues as one of the fastest growing companies
JB continues as one of the fastest growing companies, maintaining a market beating performance Among top 25, JB is the Fastest growing company fastest growing pharma Leadership position among the Top 25 in the IPM as company in the IPM in the covered markets per IQVIA MAT Sept’23 data 18% Vs IPM gro
Slide 15: Consistent Rank Improvement in the top brands
Consistent Rank Improvement in the top 6 brands MAT Sept’22 Value Sales* MAT Sept’23 Value Sales* MAT Sept’22 Rank MAT Sept’23 Rank CILACAR 292 358 #48 #35 RANTAC 314 355 #41 #37 METROGYL 173 201 #149 #146 NICARDIA 120 162 #218 #157 CILACAR-T 122 152 #212 #172 AZMARDA 90 107 - #297 14 All data as pe
Slide 16: Building Stronger Brand Franchises
Building Stronger Brand Franchises INR 390 crs INR 580 crs INR 326 crs INR 412 crs INR 224 crs INR 301 crs IQVIA MAT Sept’21 IQVIA MAT Sept’23 IQVIA MAT Sept’21 IQVIA MAT Sept’23 IQVIA MAT Sept’21 IQVIA MAT Sept’23 CILACAR T RANTAC DOM METROGYL P CILACAR M RANTAC MPS METROGYL DG CILACAR TC RANTAC RD
Slide 17: JB Chronic portfolio continues to outperform
JB Chronic portfolio continues to outperform #20 JB Pharma’s Chronic Portfolio Outperforming the IPM #21 25%* #25 12% * 10%* IPM Growth% IPM Chronic Portfolio JB Pharma Chronic Growth% Portfolio Growth% MAT Sept’21 MAT Sept’22 MAT Sept’23 As per IQVIA MAT Sept’23 data vs MAT Sept’22 numbers, JB now
Slide 18: JB Pharma ranks amongst the Top 10 in Cardiac Therapy
JB Pharma ranks amongst the Top 10 in the Cardiac Therapy; 3 brands in top 25 in Cardiology segment #08 MAT Sept'21 MAT Sept'22 MAT Sept'23 4 4 4 #11 33 28 19 #15 40 29 22 #16 3 brands in Top 25 in the Cardiology segment MAT MAT MAT MAT Sept’21 Sept’22 Sept’23 Sept’20 Addition of progressive and str
Slide 19: Sporlac: Another INR 100 crore+ franchise
Sporlac: Another INR 100 crore+ franchise 95 crores Sporlac Franchise 78 crores INR 61 crs INR 114 crs IQVIA MAT Sept’21 IQVIA MAT Sept’23 58 crores 23% 34% SPORLAC GG MAT Sept’21 MAT Sepr’22 MAT Sept’23 SPORLAC PLUS Sporlac brand is now INR 95 crore (IQVIA MAT Sept’23 SPORLAC EVA data) registering
Slide 20: International Business Q2 and H1 FY24
International Business Q2 and H1 FY24 7% 401 375 9% 263 o International business recorded revenue of INR 401 crores 242 5% in Q2 FY24 and INR 808 crores in H1 FY24 110 115 • Excluding South Africa, the business grew double- 23 23 digit in Q2 FY24 and mid-teens in H1 FY24 Total International Internat
Slide 21: Q2 and H1 FY24 Financial Performance (Consolidated)
Q2 and H1 FY24 Financial Performance (Consolidated) Particulars Q2 FY24 Q2 FY23 YoY Growth H1 FY 24 H1 FY 23 YoY Growth Revenue from Operations 882 809 9% 1778 1594 12% Cost of Goods Sold 298 302 -1% 608 594 2% Gross Profit 584 508 15% 1170 1000 17% Gross Profit Margins 66.2% 62.7% 65.8% 62.7% Emplo
Slide 22: JB Balance Sheet: Nearing zero net debt; Cash flows remain strong
JB Balance Sheet : Nearing zero net debt; Cash flows remain strong As on 30 As on 31 o Operating cash flows in H1 FY24 were INR 421 crores vs Balance Sheet (INR Cr) INR 279 crores in H1 FY23 Sept’23 Mar’23 Net Worth 2717 2480 Other Liabilities 332 287 o Gross Debt reduced to INR 427 crores as on 30t
Slide 23: JB Pharma – Looking ahead
JB Pharma – Looking ahead Growth objectives supported by lean organization structure and strong governance framework Domestic business to consistently outperform Continued growth momentum in International market growth driven by business Big brands becoming bigger Strong delivery in CDMO business ai
Slide 24: Sustainability Report – FY 2022 - 2023
Sustainability Report – FY 2022 - 2023 Reporting Framework: Report prepared in accordance with the GRI 2021 Standards United Nations Sustainable Development Goals (UN SDGs) Reporting Period: This report covers the sustainability performance of the Company for the period 1st April 2022 till 31st Marc
Slide 25: About JB Pharma
About JB Pharma J.B. Pharma (BSE: 506943 | NSE: JBCHEPHARM | For further information, please ISIN: INE572A01028), established in 1976, is one contact: of the fastest growing pharmaceutical companies in India and a leading player in the hypertension Lakshay Kataria, Chief Financial Officer segment. B
Slide 26: Thank you
Thank you www.jbpharma.com 25
J. B. Chemicals & Pharmaceuticals — Q2 FY24 Earnings Presentation on 6ix